Rattlesnake Venom Compounds Show Activity Against Hepatitis C Virus
A group of Brazilian scientists achieved promising results using isolated compounds from the venom of the South American rattlesnake in combat of hepatitis C. The investigation was based on records in scientific literature in which animal venom have shown activity against some viruses, such as yellow fever, measles and dengue - the latter belongs to the same virus family as hepatitis', the Flaviviridae family.
There is a great need for new methods in the fight against hepatitis C. The therapies available are expensive, have adverse side effects, and entail viral resistance. In Sao Paulo State, Brazil, some 50% of liver transplants in São Paulo State are performed on hepatitis B or C patients, according to the state's health department. Hepatitis C patients alone account for 40% of all liver transplants in São Paulo.
This investigation was carried out by researchers affiliated with the Institute of Biosciences, Letters & Exact Sciences - IBILCE of the São Paulo State University - UNESP (municipality of Sao Jose do Rio Preto's campus), the Institute of Biomedical Sciences - ICBIM of the Federal University of Uberlandia - UFU and the School of Pharmaceutical Sciences of the University of Sao Paulo - USP (municipality of Ribeirao Preto's campus).
Through the support from a number of funding institutions - namely FAPESP (Sao Paulo Research Foundation), Fapemig (Minas Gerais State Agency for Research and Development), CNPq (National Council for Scientific & Technological Development) and Newton Fund (Royal Society, UK), the researchers not only were able to test three compounds from the venom of Crotalus durissus terrificus rattlesnake but also investigated the antiviral potential of flavonoids extracted from Pterogyne nitens, a kind of plant endemic to Brazil.
Results from these experiments were published in PloS One and Scientific Reports, respectively.
In the Laboratory of Toxicology at FCF-USP, two proteins from the rattlesnake venom were successfully isolated, phospholipase A2 (PLA2-CB) and crotapotin (CP). They are found in natura as subunits of the crotoxin protein complex, which the researchers also tested.
In a series of in vitro experiments with cultured human cells, they tested the antiviral action of the two compounds, both separately and together in the protein complex. They observed the compounds' effects on human cells (to help prevent infection by the virus) and directly on hepatitis C virus.
The hepatitis C virus's genome consists of a single strand of RNA (ribonucleic acid), which is a simple chain of nucleotides encoding the proteins in the virus.
"This virus invades the human host cell to replicate, producing new viral particles. Inside the host cell, the virus produces a complementary strand of RNA, from which molecules of viral genome will emerge to constitute the new particles," said Ana Carolina Gomes Jardim, head of the Virology Laboratory in ICBIM-UFU.
"Our research showed that phospholipase can intercalate into double-stranded RNA, a virus replication intermediate, inhibiting the production of new viral particles. Intercalation reduced these by 86% compared with their production in the absence of phospholipase."
When the same experiment was performed using crotoxin, production of viral particles fell 58%.
The second stage of the research consisted of verifying whether the compounds blocked the virus's entry into cultured human cells. In this case, the results were even more satisfactory: phospholipase blocked 97% of viral cell entry, and crotoxin reduced viral infection by 85%.
Lastly, they tested crotapotin, another compound isolated from the same rattlesnake's venom. Crotapotin had no inhibitory effect on viral entry or replication but did affect another stage of the virus's life cycle, reducing release of new viral particles from cells by 78%. Treatment with crotoxin achieved 50% inhibition of viral release.
According to the researchers, the results of the experiments show that phospholipase and crotapotin produced better results when used separately than together.
The second article on the action of chemical compounds against hepatitis C virus describes substances derived from Brazilian flora: sorbifolin and pedalitin, both flavonoids isolated from the leaves of Pterogyne nitens during the experiments conducted by Professor Luis Octávio Regasini at UNESP's Green & Medicinal Chemistry Laboratory in Sao José do Rio Preto.
Flavonoids are compounds found in fruit, flowers, vegetables, honey, and wine. As with the compounds isolated from rattlesnake venom, the flavonoids were tested for antiviral action in human cells infected with hepatitis C virus and in uninfected cells.
"Sorbifolin blocked viral entry into human cells in 45% of cases, while pedalitin provided more promising results, blocking entry in 79% of cases. The experiment was performed with two genotypes of hepatitis C virus: genotype 2A, the standard type in all studies, and genotype 3, the second most prevalent in Brazil. In both cases, the antiviral action of the flavonoids was equivalent," Gomes Jardim said.
At the other end of the viral life cycle, the flavonoids had no effect on viral particle replication and did not prevent their release from infected cells.
"The flavonoids from P. nitens are among some 200 tested compounds isolated from Brazilian plants or synthesized using natural structures by Professor Regasini," said Paula Rahal, who coordinates the Virology Group at the Genomic Studies Laboratory at IBILCE-UNESP. "These two flavonoids were tested against hepatitis C virus because they'd been shown to have antiviral action in experiments with dengue virus."
This article has been republished from materials provided by Fundação De Amparo À Pesquisa Do Estado De São Paulo. Note: material may have been edited for length and content. For further information, please contact the cited source.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.